Opinion|Videos|February 6, 2026
Safety Considerations for Frontline Regimens in EGFR+ NSCLC
Explore the impact of CNS metastasis on prognosis in EGFR mutant lung cancer and the promising results from the MARIPOSA trial.
Advertisement
Episodes in this series
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, FACP, FASCO, outline key safety profiles of frontline regimens used in EGFR-mutated NSCLC. They discuss common adverse events, monitoring strategies, and dose modification approaches. They also emphasize balancing efficacy with tolerability in long-term disease management.
Advertisement
Related to this article
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Katie S. Murray, DO, discusses how efficacy, toxicity, patient preferences, and treatment logistics guide BCG-unresponsive NMIBC care.
Vignesh T. Packiam, MD, reviews why improved BCG outcomes support its first-line use, with gemcitabine/docetaxel as a BCG-sparing option.
Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
4
Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026
5